Literature DB >> 26171062

Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma.

Zhixiong Long1, Bin Wang1, Dan Tao2, Yanping Liu2, Jiangzhou Zhang2, Jiaan Tan3, Jing Luo3, Feifei Shi3, Zezhang Tao1.   

Abstract

The delivery of high tumoricidal doses of radiation with low rates of toxicity is of particular significance for massive hepatocellular carcinoma (HCC) radiotherapy. In order to observe the efficacy and adverse reactions of alternating hyperfraction radiotherapy treatment of massive HCC, seventy-two cases of massive HCC were randomly divided into two groups, group A and group B. The liver lesions of group A were divided into sublesions and treated with alternating hyperfraction radiotherapy [intensity modulated radiotherapy (IMRT)]. The interval between radiotherapy to the sublesions was a minimum of six hours. The average radiotherapy dose to the sublesions was 2 Gy/fraction, once a day, five times per week, treating the gross tumor volume with a total dose of 40-50 Gy, and the clinical target volume with a total dose of 30-40 Gy. By contrast, the lesions of group B were not divided into sublesions for the IMRT treatment, but were treated with an otherwise identical protocol, by 2 Gy/fraction, once a day, five times per week, and with the same total dose. Patients were followed up with regular blood tests, liver function tests, measurements of serum α-fetoprotein levels and contrast-enhanced magnetic resonance imaging (MRI) of the liver. Treatment responses were assessed every 3 months by MRI. The results revealed that the overall response rates of the two groups were 82.9 and 81.3%, respectively (P=0.864). The alternating hyperfraction radiotherapy protocol resulted in enhanced survival (P=0.002). The median survival time of the two groups was 9.7 and 6.5 months, respectively. The overall 6-month, 1-year, 2-year and 3-year survival rates of the two groups were 62.9 and 59.4% (P=0.770), 48.6 and 21.9% (P=0.040), 17.1 and 0.0% (P=0.025) and 2.9 and 0.0% (P=1.000), respectively. The I-II degree of abnormal liver function and radiation-induced liver disease of group B was higher than that of group A (P=0.021 and 0.046, respectively). In addition, the incidence rate of radiation-induced liver injury of group A was lower than that of group B. Therefore, treatment of massive HCC with alternating hyperfraction radiotherapy improved the quality of life and prolonged the overall survival time, compared with conventional IMRT, suggesting that it was an effective radiation pattern.

Entities:  

Keywords:  alternating hyperfraction radiotherapy; massive hepatocellular carcinoma; radiation-induced liver disease

Year:  2015        PMID: 26171062      PMCID: PMC4487099          DOI: 10.3892/ol.2015.3185

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

Review 1.  3D treatment planning and intensity-modulated radiation therapy.

Authors:  J A Purdy
Journal:  Oncology (Williston Park)       Date:  1999-10       Impact factor: 2.990

2.  International trends in liver cancer incidence rates.

Authors:  Melissa M Center; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-15       Impact factor: 4.254

Review 3.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma.

Authors:  Zhao-Chong Zeng; Zhao-You Tang; Jia Fan; Jian Zhou; Lun-Xiu Qin; Shen-Long Ye; Hui-Chuan Sun; Bin-Liang Wang; Yao Yu; Jian-Hua Wang; Wei Guo
Journal:  Cancer J       Date:  2004 Sep-Oct       Impact factor: 3.360

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma.

Authors:  Hong In Yoon; Ik Jae Lee; Kwang-Hyub Han; Jinsil Seong
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-09       Impact factor: 4.553

Review 7.  Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities.

Authors:  Jonathan Klein; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-06       Impact factor: 7.038

8.  Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma.

Authors:  Brian I Carr; Vito Guerra; Petr Pancoska
Journal:  Oncology       Date:  2012-09-18       Impact factor: 2.935

Review 9.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07

10.  A comparison of liver protection among 3-D conformal radiotherapy, intensity-modulated radiotherapy and RapidArc for hepatocellular carcinoma.

Authors:  Dong Chen; Renben Wang; Xiangjiao Meng; Tonghai Liu; Hongjiang Yan; Rui Feng; Shangang Liu; Shumei Jiang; Xiaoqing Xu; Kunli Zhu; Xue Dou
Journal:  Radiat Oncol       Date:  2014-02-06       Impact factor: 3.481

View more
  3 in total

1.  Defining Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma Patients Treated with Stereotactic Body Radiotherapy.

Authors:  Jin Ho Song; Bae-Kwon Jeong; Hoon-Sik Choi; Hojin Jeong; Yun Hee Lee; Hong Jun Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee; Hong Seok Jang; Byung Ock Choi; Ki Mun Kang
Journal:  J Cancer       Date:  2017-11-12       Impact factor: 4.207

2.  Toll-like receptor 4 and its associated proteins as prognostic factors for HCC treated by post-radiotherapy surgery.

Authors:  Zhi-Feng Wu; Ying Wang; Ping Yang; Jia-Zhou Hou; Jian-Ying Zhang; Yong Hu; Zhao-Chong Zeng
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

3.  Comparison of Combination Stereotactic Body Radiotherapy Plus High-Intensity Focused Ultrasound Ablation Versus Stereotactic Body Radiotherapy Alone for Massive Hepatocellular Carcinoma.

Authors:  Lei Wang; Lingzhao Li; Xiaofang Wang; Di Zhao; Guoyong Shan; Xiaodong Wu; Mengli Wang; Junqi Liu; Xingya Li
Journal:  Med Sci Monit       Date:  2018-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.